𝛼SK or Search

ENTITY

Shenzhen Hepalink Pharmaceutical (9989 HK)

97

Analysis

Health Care • China

Shenzhen Hepalink Pharmaceutical is a multinational biopharmaceutical company with core businesses in the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. Its key products include heparin sodium APIs and enoxaparin sodium preparations. The company is headquartered in Shenzhen, China, and was founded in 1998.

more

Refresh

Exchange Announcement • 22 Sep 2026 19:04

Poll Results Of The 2026 First Extraordinary General Meeting Held On September 22, 2026

Exchange Announcement • 18 Sep 2026 16:31

2026 Interim Report

Exchange Announcement • 31 Aug 2026 18:38

Notice Of The 2026 First Extraordinary General Meeting

Exchange Announcement • 31 Aug 2026 18:36

Proxy Form For The 2026 First Extraordinary General Meeting To Be Held On Tuesday, September 22, 2026

Exchange Announcement • 31 Aug 2026 18:29

Proposed Increase To The Limit For Purchase Of Wealth Management Products And Cash Flow Management Using Internal Funds Proposed Adjustment To The Credit Line And Guarantee Limit And Notice Of The 2026 First Extraordinary General Meeting

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x